A Drug-drug Interaction Study With TS-172 in Healthy Adult Male Subjects

PHASE1CompletedINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

March 11, 2025

Primary Completion Date

April 30, 2025

Study Completion Date

April 30, 2025

Conditions
Healthy Male Subjects
Interventions
DRUG

Triazolam and TS-172

Oral single administration of triazolam 0.25 mg at single administration phase, followed by a oral single administration of triazolam 0.25 mg and TS-172 20 mg at concomitant administration phase

DRUG

TS-172 and itraconazole

Oral single administrtation of TS-172 20 mg at single administration phase, followed by a oral single administration of TS-172 and itoraconazole 200 mg at concomitant administration phase

Trial Locations (1)

Unknown

Taisho Pharmaceutical Co., Ltd selected site, Tokyo

All Listed Sponsors
lead

Taisho Pharmaceutical Co., Ltd.

INDUSTRY

NCT06837142 - A Drug-drug Interaction Study With TS-172 in Healthy Adult Male Subjects | Biotech Hunter | Biotech Hunter